International Copper Study Group (ICSG) says global refined copper market recorded a 145,000-tonne deficit in April 2026.

Micron Technology (MU.O) says R&D on next-generation DRAM and NAND nodes is progressing well and expects to begin mass production in H2 2027.

WuXi Biologics said its MFG17 biologics drug-substance plant at the Shanghai Fengxian campus completed its first GMP production. MFG17 is the company’s 25th global drug-substance facility and will provide scaled clinical and commercial supply for multiple biologics. The plant is equipped with multiple single-use bioreactors (SUBs), has 9,000‑liter capacity and is designed for about 80–100 drug-substance batches a year.